BOSTON, June 22, 2017 /PRNewswire/ -- Balter Liquid Alternatives LLC ("BLA"), one of the leading players in the growing liquid alternative business and subsidiary of Balter Capital Management ("BCM"), announced today the launch of the Balter Invenomic Fund (ticker: BIVIX), an all-cap long/short equity¹ mutual fund, sub-advised by Invenomic Capital Management, based in Boston. Invenomic was founded by Ali Motamed, former Co-Portfolio Manager for the Boston Partners Long/Short Equity Fund (BPLSX). He was Morningstar's Alternative Fund Manager of the year in 2014.
BLA has entered into a strategic partnership with Invenomic and will run operations and compliance for the firm. Motamed will utilize the same investment process that he developed during his time at Boston Partners.
Invenomic's investment process utilizes quantitative analysis on the front end coupled with fundamental analysis on the back end. The quantitative process is used to source potentially attractive long and short ideas that then go through fundamental analysis to determine whether they are appropriate for the portfolio. Motamed seeks to invest in companies that generate strong cash flows and deploy capital well on the long side and companies that are overvalued and destroy capital on the short side. The fund will have a variable net exposure that will be dictated by short opportunities. The fund's net exposure is expected to be low during overvalued markets and high during undervalued markets. The fund will invest in both large and small companies predominately in the United States.
Brad Balter, CEO of Balter Liquid Alternatives LLC says, "We are thrilled to be partnering with Invenomic on the launch of this fund. Our partnership with Invenomic further enhances our mission of bringing the highest quality alternative mutual funds in the industry to market. The Balter Invenomic Fund continues our tradition of launching capacity constrained strategies run by experienced investment managers. Ali is proven talent in managing liquid long/short equity portfolios and we couldn't be happier partnering with him and his firm."
Ali Motamed adds, "We are extremely excited to be partnering with Balter Liquid Alternatives to bring the Balter Invenomic Fund to investors. Brad and his team have a proven ability to deliver the highest levels of compliance and operational oversight, which will allow my team and I to dedicate ourselves to the investment process. This partnership presents a unique opportunity for us to offer mutual fund investors what we believe has historically been a successful strategy outside the inherent constraints of a multi-billion investment firm."
Unlike traditional hedge funds, many alternative mutual funds provide daily liquidity, lower investment minimums, and simplified tax reporting for shareholders, while offering quarterly full transparency of portfolio holdings and lower fees. BLA funds employ the investment approach, risk management and operational due diligence typically available only to institutional and high net worth investors through traditional hedge fund structures.
"Liquid Alternatives are going through a period of consolidation where investors are trying to separate the wheat from the chaff," said Balter. "The proliferation of new liquid alternative funds over the last three years have left investors seeking clarity on the numerous offerings available to the them. Our mission remains the same, provide investors with the highest quality liquid alternative offerings in the industry."
About Balter Liquid Alternatives
Balter Liquid Alternatives (BLA) is a subsidiary of Balter Capital Management, a boutique research firm focused on hedge fund research and investing. BLA was formed to create and manage daily liquidity alternative mutual funds. Balter Capital Management oversees approximately $1.3 Billion in hedge fund and alternative mutual fund assets. BLA constructs liquid investment products utilizing existing hedge fund managers. For more information, please visit our website at www.balterliquidalts.com.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Balter Funds. This and other important information about the Funds is contained in the prospectus, which can be obtained at www.balterliquidalts.com or by calling 844-322-8112. The prospectus should be read carefully before investing.
Mutual funds involve risks including the possible loss of principal. There can be no assurance that the fund advisers will be effective in achieving the fund's investment objectives, delivering positive return or avoiding losses. Additional information regarding the risks associated with an investment in each of the funds can be located in the fund's prospectus. Short sales of securities may result in gains if a security's price declines, but may result in losses if a security's price rises. Liquidity does not ensure profit or prevent losses.
The Balter Funds are distributed by Northern Lights Distributors, LLC, member FINRA/SIPC. Balter Liquid Alternatives is not affiliated with Northern Lights Distributors, LLC.
¹Long/short equity is an investing strategy of taking long positions in stocks that are expected to appreciate and short positions in stocks that are expected to decline. A long/short equity strategy seeks to minimize market exposure, while profiting from stock gains in the long positions and price declines in the short positions.
CONTACT: Bob Marx, 617-742-2210, firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/balter-liquid-alternatives--ali-motameds-invenomic-capital-partner-to-launch-the-balter-invenomic-fund-bivix-300477841.html
SOURCE Balter Liquid Alternatives LLC